Using engineered RNA to enhance cancer immunotherapy
Immunotherapy via engineered therapeutic programs in tumors using RNA
This study is exploring a new way to treat cancer by using tiny particles to deliver special RNA directly into tumors, helping the immune system fight the cancer more effectively, and it's designed for patients with solid tumors that are hard to treat.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10906178 on NIH RePORTER |
What this research studies
This research investigates a novel approach to cancer treatment by utilizing synthetic lipid nanoparticles to deliver self-replicating RNA directly into tumors. This method aims to activate the immune system's response against cancer cells, potentially leading to tumor regression. The study focuses on improving the effectiveness of immunotherapy in solid tumors, which have been challenging to treat with existing therapies. By combining advanced synthetic biology techniques, the research seeks to create safer and more effective therapeutic options for patients with various types of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who have not responded adequately to current immunotherapy treatments.
Not a fit: Patients with non-solid tumors or those who have already achieved remission may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for patients with solid tumors by enhancing the immune system's ability to target and destroy cancer cells.
How similar studies have performed: Other research has shown promising results using similar RNA-based immunotherapy approaches, indicating potential for success in this novel application.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Weiss, Ron — Massachusetts Institute of Technology
- Study coordinator: Weiss, Ron
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.